RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--May 22, 2006--Talecris Biotherapeutics, a leading global biological products and biotech company, is making available a compendium of classic papers in the area of alpha-1 antitrypsin (AAT) deficiency in honor of the 20th anniversary of the filing of the Biologic License Application (BLA) for Prolastin® (Alpha-1 Proteinase Inhibitor (Human)). The compendium, entitled "Alpha-1 Antitrypsin Deficiency: A History Through the Medical Literature," brings together key publications from the last 40 years that have increased understanding the pathogenesis, prevalence, and effective treatment of the disease.
